Clinical Trials Logo
  1. Home
  2. Stomach Diseases
  3. NCT02476097

PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms — PROGRESS  

Stomach Diseases Clinical Trial

Official title:
Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study

Clinical Trial Summary

Rebound acid hypersecretion (RAHS), defined as an increase in gastric acid secretion above pre-treatment levels after PPIs therapy is observed within two weeks after withdrawal of treatment and could theoretically lead to acid-related symptoms such as heartburn, acid regurgitation, or dyspepsia that might result in resumption of therapy. A plausible physiologic theory for the rebound phenomenon suggests that long-term, elevated gastric pH caused by blockage of the proton-pumps stimulates compensatory gastrin release. Interestingly, Reimer et al. demonstrated the occurrence of RAHS in healthy volunteers who had received eight weeks of esomperazole. The clinical symptoms occured in a different prevalence compared with placebo treated patients at ten weeks after withdrawal and until the end of the study (twelve weeks). Twenty to twenty-two percent of patients displayed symptoms ten or twelve weeks after having discontinued PPIs while they occured in 1.7-7% of placebo-treated patients. Efforts should be pursued to restrict PPI therapy use to patients likely to benefit from it. In this context, we propose to investigate the benefit of a progressive decrease in doses of esomeprazole compared to a sudden discontinuation. This is a randomized, double-blind, placebo-controlled trial with 156 patients treated by esomeprazole 40mg since four weeks least, randomized to one week of placebo or one week of esomeprazole 20mg. We want to compare the prevalence of clinical gastrointestinal symptoms between patients with progressive discontinuation (one week of esomeprazole, 20mg, then discontinuation) or those with sudden discontinuation of esomeprazole 40mg.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02476097
Study type Interventional
Source University Hospital, Geneva
Contact
Status Active, not recruiting
Phase Phase 4
Start date June 2015
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05069233 - Magnetically Controlled Capsule Endoscopy in Visualization of the UGI and Small Intestine
Completed NCT00745459 - Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy Phase 3
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00977678 - Drop in Gastroscopy - Experience After 9 Months N/A
Terminated NCT00577772 - Transit Time and Bacterial Overgrowth Using SmartPill Capsule N/A
Completed NCT03514966 - Repetitive Position Change Improves Gastric Cleanliness for MCE N/A
Recruiting NCT02846155 - Gastric Preparation of Magnetic-controlled Capsule Endoscopy Phase 2
Not yet recruiting NCT03889626 - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Phase 3
Completed NCT01576380 - A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients Phase 2
Completed NCT00682877 - A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old N/A
Completed NCT00128284 - A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time N/A
Completed NCT01420588 - Diagnosis of Gastric Lesions From Exhaled Breath and Saliva